Page last updated: 2024-11-05

amopyroquine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

amopyroquine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25194
CHEMBL ID1213257
SCHEMBL ID249505
MeSH IDM0054908

Synonyms (29)

Synonym
CHEMBL1213257
amopyroquine
FT-0662120
4-[(7-chloroquinolin-4-yl)amino]-2-(pyrrolidin-1-ylmethyl)phenol
phenol, 4-((7-chloro-4-quinolinyl)amino)-2-(1-pyrrolidinylmethyl)-
amopyroquinum
4-(7-chlor-4-chinolylamino)-2-(1-pyrrolidinylmethyl)phenol
amopyroquina [inn-spanish]
4-((7-chloro-4-quinolyl)amino)-alpha-1-pyrrolidinyl-o-cresol
unii-sv6l22y9qf
550-81-2
amopyroquine [inn]
amopyrochinum
o-cresol, 4-((7-chloro-4-quinolyl)amino)-alpha-1-pyrrolidinyl-
amopyroquinum [inn-latin]
amopyroquina
amopyroquin
pam-780
sv6l22y9qf ,
4-[(7-chloro-4-quinolinyl)amino]-2-(1-pyrrolidinylmethyl)phenol
SCHEMBL249505
4-[(7-chloro-4-quinolinyl)amino]-2-(1-pyrrolidinylmethyl)phenol #
YNWCUCSDUMVJKR-UHFFFAOYSA-N
4-[(7-chloro-4-quinolyl)amino]-.alpha.-1-pyrrolidinyl-o-cresol
DTXSID50203544
AKOS030239783
amopyroquin; pam-780; propoquin
Q27289420
4-[(7-chloro-4-quinolyl)amino]-alpha-1-pyrrolidinyl-o-cresol

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" After a rapid absorption phase (15 min), levels in plasma declined, following a tri-exponential model with a terminal elimination half-life of 129."( Pharmacokinetics of intramuscular amopyroquin in healthy subjects and determination of a therapeutic regimen for Plasmodium falciparum malaria.
Clavier, F; Gaudebout, C; Le Bras, J; Pussard, E; Verdier, F, 1989
)
0.28

Bioavailability

ExcerptReferenceRelevance
" The similar bioavailability values (0."( Disposition of amopyroquin in rats and rabbits and in vitro activity against Plasmodium falciparum.
Clavier, F; Faurisson, F; Gaudebout, C; Pussard, E; Simon, F; Verdier, F, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID738328Binding affinity to recombinant heparanase catalytic stie (unknown origin) expressed in Escherichia coli BL21 (DE3) by surface plasmon resonance assay2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID738326Binding affinity to recombinant heparanase catalytic stie (unknown origin) expressed in Escherichia coli BL21 (DE3) by saturation transfer difference analysis2013Bioorganic & medicinal chemistry, Apr-01, Volume: 21, Issue:7
Hit identification of novel heparanase inhibitors by structure- and ligand-based approaches.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (62.50)18.7374
1990's4 (25.00)18.2507
2000's0 (0.00)29.6817
2010's2 (12.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other18 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]